Literature DB >> 2020767

Radiotherapy and anaemia--the clinical experience.

S Dische1.   

Abstract

Review of the literature shows good evidence of an impaired outlook for anaemic compared with apparently similar, but non-anaemic patients, treated by radiotherapy for tumors at a number of sites. Some of the adverse associations, may be because anaemic patients, compared with the non-anaemic at the same site and with the same clinical stage, may have in actuality a more advanced disease. However, there is good evidence, especially in carcinoma of the cervix, that there occurs an impairment of the response of tumor to radiotherapy in anaemic patients. Where cure is the object of radiotherapy, restoration of the haemoglobin level is necessary before the course is begun. During the past 60 years there has been much interest in the relationship between anaemia and response to radiotherapy. In 25 series of cases where an effect of anaemia has been sought an adverse influence has been found in 23. An examination of these papers, however, reveals a complex pattern demanding some analysis. Anaemia itself requires definition. As can be seen in Fig. 1, there are different normal ranges for men and women and there is some variation in what is accepted as normal. Haemoglobin levels are commonly given in g%, but they are also expressed as mmol/l. There are also reports which refer to the haematocrit. The haemoglobin value at first presentation may be recorded, but the picture may change by the time treatment is instituted, either because of haemorrhage or because of blood transfusion. In examining reports it is sometimes not easy to know which value is related to response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 2020767     DOI: 10.1016/0167-8140(91)90184-i

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  15 in total

1.  Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Authors:  Javier Valencia Julve; Vicente Alonso Orduña; Ricardo Escó Barón; Miriam López-Mata; Agustina Méndez Villamón
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  A practical prognostic index for inoperable non-small-cell lung cancer.

Authors:  T Wigren; H Oksanen; P Kellokumpu-Lehtinen
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  A randomised study of ornidazole as a radiosensitiser in carcinoma of the cervix: long term results.

Authors:  S Okkan; G Atkovar; I Sahinler; S Turkan; R Uzel
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 4.  Hypoxia and anaemia in patients with cancer of the uterine cervix.

Authors:  Francisco José Andreu-Martínez; Julia M Martínez-Mateu
Journal:  Clin Transl Oncol       Date:  2005-09       Impact factor: 3.405

Review 5.  Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.

Authors:  M Saunders; S Dische
Journal:  Br J Cancer Suppl       Date:  1996-07

6.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 7.  The clinical value of erythropoietin in patients with cancer.

Authors:  Ulrich Dührsen
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 8.  Hematopoietic growth factors and the treatment of tumor-associated anemias.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

Review 9.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial.

Authors:  P J Sweeney; D Nicolae; L Ignacio; L Chen; M Roach; W Wara; K C Marcus; S Vijayakumar
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.